Pericytes are mesenchymal-derived cells that wrap around endothelial cells forming the capillary wall. They play crucial roles in blood-brain barrier (BBB) maintenance, angiogenesis, vascular stability, and immune cell trafficking. Pericytes are strategically positioned between endothelial cells and astrocytes, forming a critical component of the neurovascular unit. Their dysfunction has been increasingly recognized as a key contributor to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological disorders. First described by Charles Rouget in 1873 and later studied extensively by Wilhelm Zimmermann in the 1920s, pericytes have emerged as essential regulators of CNS homeostasis[1]. [1]
Pericytes are irregularly shaped cells with multiple processes that extend along capillaries, pre-capillary arterioles, and post-capillary venules. They communicate with endothelial cells through direct physical contact (peg-and-socket junctions) and paracrine signaling. The coverage ratio of pericytes to endothelial cells varies across brain regions, with higher pericyte density in cortical areas compared to white matter. This heterogeneity likely contributes to regional susceptibility to vascular damage in neurodegenerative diseases[2]. [2]
In the human brain, pericyte density averages approximately 60-80 per capillary, with each pericyte contacting multiple endothelial cells along a 50-100 μm segment. Their cytoplasmic processes contain smooth muscle actin (α-SMA) filaments, particularly in pre-capillary arterioles, enabling contractile function for blood flow regulation. Pericyte morphology varies significantly depending on their location within the vascular tree, with those on pre-capillary arterioles exhibiting more extensive smooth muscle cell-like characteristics compared to those on capillaries[3]. [3]
The three main morphological subtypes of brain pericytes include: (1) Type I pericytes found on pre-capillary arterioles with high α-SMA content and strong contractile capabilities, (2) Type II capillary pericytes representing the most abundant subtype with moderate α-SMA expression and extensive perivascular coverage, and (3) Type III post-capillary venular pericytes involved in immune cell trafficking with elevated adhesion molecule expression[4]. [4]
Key markers for pericyte identification include: [5]
Comprehensive identification requires multiple marker assessment, as no single marker is completely specific for pericytes. Studies indicate that PDGFR-β and NG2 co-expression provides the most reliable identification in adult brain tissue[11]. [6]
Pericytes are essential for BBB formation and maintenance. They regulate endothelial tight junction proteins (claudin-5, occludin, ZO-1), control endothelial transporter expression, and influence leukocyte trafficking. Pericyte deficiency leads to increased BBB permeability, reduced tight junction integrity, and altered endothelial gene expression[12]. The physical coverage provided by pericytes also limits transendothelial leakage, with studies showing 50% reduction in pericyte coverage leads to significant plasma protein extravasation into brain parenchyma[13]. [7]
Mechanistically, pericytes maintain BBB integrity through multiple pathways: (1) secretion of factors promoting tight junction protein expression, (2) regulation of endothelial transporter systems including P-glycoprotein and GLUT1, (3) contribution to basement membrane formation and maintenance, and (4) physical barrier function through extensive coverage of the abluminal endothelial surface[14]. [8]
The developmental timeline of BBB formation demonstrates pericyte recruitment is essential for barrier maturation. During embryogenesis, endothelial PDGF-B secretion attracts PDGFR-β-expressing pericytes, which then proliferate and spread along developing vessels. Loss of either PDGF-B or PDGFR-β signaling results in pericyte deficiency and leaky BBB[15]. [9]
During development, PDGF-B secreted by growing endothelial cells attracts PDGFR-β-expressing pericytes, establishing the pericyte-endothelial relationship. Pericytes secrete VEGF-A and other angiogenic factors that promote endothelial proliferation and tube formation. In mature vessels, pericytes provide structural support and coordinate vasodynamic responses through gap junctions with endothelial cells and smooth muscle cells[16]. [10]
Pericytes contribute to vascular stability through: (1) secretion of angiopoietin-1 that promotes endothelial survival and junctional integrity, (2) production of PDGF-B for autocrine pericyte survival signaling, (3) extracellular matrix deposition providing structural support, and (4) physical envelope limiting endothelial proliferation and remodeling[17]. [11]
Pericytes, particularly those on pre-capillary arterioles, possess contractile machinery allowing them to regulate capillary diameter and blood flow in response to neural activity (neurovascular coupling). They respond to neurotransmitters (norepinephrine, acetylcholine), astrocytic signals (calcium waves, prostaglandins), and metabolic demands (adenosine, ATP). Pericyte constriction can reduce capillary flow by up to 40%, making them active participants in functional hyperemia[18]. [12]
The neurovascular coupling cascade involves: (1) neural activity triggers astrocytic calcium waves, (2) astrocyte end-feet release prostaglandins and epoxyeicosatrienoic acids (EETs), (3) pericytes relax in response, causing capillary dilation, (4) increased blood flow matches metabolic demand[19]. This mechanism is compromised in neurodegenerative diseases, contributing to hypoperfusion and metabolic dysfunction. [13]
Pericytes express adhesion molecules (ICAM-1, VCAM-1) that facilitate leukocyte rolling and adhesion during inflammation. They produce cytokines and chemokines (IL-6, MCP-1, MIP-1α) that recruit immune cells. In pathological states, pericytes can transform into pro-inflammatory phenotypes, secreting matrix metalloproteinases (MMP-2, MMP-9) that degrade basement membranes and exacerbate BBB disruption[20]. [14]
Pericyte involvement in neuroinflammation includes: (1) detection of pathogen-associated molecular patterns (PAMPs), (2) secretion of pro-inflammatory cytokines amplifying immune responses, (3) upregulation of adhesion molecules enabling leukocyte extravasation, and (4) production of matrix metalloproteinases that modify the extracellular environment[21]. [15]
Post-mortem brain studies reveal significant pericyte loss in AD patients, with 30-50% reduction in pericyte coverage compared to age-matched controls. This loss correlates with amyloid angiopathy, micro hemorrhages, and cognitive decline. Amyloid-beta (Aβ) deposits frequently accumulate around pericytes, suggesting direct toxicity. Genome-wide association studies have identified variants in genes regulating pericyte function (APOE ε4, CLU) as risk factors for sporadic AD[22][23]. [16]
Quantitative analysis of AD brain tissue demonstrates: (1) 30-50% reduction in pericyte coverage in cortical and hippocampal regions, (2) correlation between pericyte loss and BBB permeability as measured by plasma protein extravasation, (3) spatial relationship between pericyte loss and amyloid plaque burden, and (4) association between pericyte deficiency and cognitive impairment[24]. [17]
Amyloid-Beta Toxicity: Aβ binds to pericyte PDGFR-β, triggering internalization and degradation of the receptor. This impairs PDGF-B signaling, necessary for pericyte survival, leading to pericyte death. Aβ also induces oxidative stress in pericytes through NADPH oxidase activation[25]. [18]
Tau Pathology: Hyperphosphorylated tau accumulates in pericytes in AD brains, correlating with pericyte degeneration. Tau pathology may disrupt pericyte cytoskeletal organization and contractile function. Studies show tau-laden pericytes demonstrate cytoplasmic vacuolization and reduced viability[26]. [19]
Reduced PDGF-B Signaling: Endothelial PDGF-B expression decreases with aging and AD progression, reducing pericyte recruitment and maintenance. This creates a feed-forward loop where pericyte loss worsens vascular dysfunction[27]. [20]
Pericyte dysfunction contributes to AD through multiple mechanisms: [21]
BBB Breakdown: Leads to extravasation of blood-borne proteins and immune cells into brain parenchyma, promoting neuroinflammation. Studies demonstrate 5-10-fold increases in plasma protein leakage in pericyte-deficient regions[28].
Impaired Aβ Clearance: Pericytes participate in perivascular drainage of Aβ along arteriolar basement membranes. Their loss impairs this clearance pathway, contributing to amyloid accumulation. Pericyte-deficient mice show 2-3-fold increased Aβ deposition[29].
Cerebral Amyloid Angiopathy: Pericyte deficiency promotes Aβ deposition in cerebral blood vessels, causing hemorrhages and further compromising blood flow[30].
Hypoperfusion: Reduced pericyte-mediated vasodilation decreases cerebral blood flow, contributing to hypometabolism observed in AD. Neurovascular uncoupling blunts activity-dependent blood flow increases[31].
Neurovascular Uncoupling: Impaired functional hyperemia blunts activity-dependent blood flow increases necessary for synaptic function, contributing to cognitive decline[32].
While less extensively studied than in AD, evidence indicates pericyte dysfunction contributes to PD pathogenesis. Post-mortem studies show reduced pericyte coverage in PD substantia nigra, where vascular density is normally high to support high metabolic demand of dopaminergic neurons. Pericyte loss in this region may exacerbate dopaminergic neuron vulnerability[33]. [22]
Quantitative studies reveal: (1) 40-60% reduction in pericyte coverage in substantia nigra, (2) correlation between pericyte loss and dopaminergic neuron loss, (3) regional specificity with greater vulnerability in affected brain regions, and (4) association with disease severity[34]. [23]
BBB disruption has been documented in PD patients, with serum protein extravasation observed in the substantia nigra and striatum. Pericyte injury may be an early event in PD pathogenesis, preceding overt neuronal loss. Studies in mouse models show α-synuclein aggregation can directly impair pericyte function through mitochondrial dysfunction and oxidative stress[35][36]. [24]
The glymphatic system, which facilitates cerebrospinal fluid-interstitial fluid exchange and Aβ clearance, depends on perivascular astrocyte end-feet and pericyte function. Pericyte loss disrupts this clearance system, potentially contributing to α-synuclein and Aβ accumulation in PD[37]. [25]
Pericyte dysfunction has been reported in ALS motor cortex and spinal cord, characterized by reduced coverage, basement membrane abnormalities, and altered PDGFR-β expression. Vascular pathology precedes motor neuron degeneration in some cases, suggesting a potential role in disease initiation[38]. Studies demonstrate 30-40% reduction in pericyte coverage in spinal cord and motor cortex of ALS patients. [26]
Pericytes contribute to immune cell trafficking across the BBB in MS lesions. Their loss or activation can promote leukocyte extravasation and inflammatory demyelination. Pericyte coverage correlates with lesion severity and remyelination success[39]. In active lesions, pericytes demonstrate increased expression of MMPs and adhesion molecules. [27]
Pericytes are primary targets in small vessel disease, contributing to white matter lesions, lacunes, and microinfarcts. Their dysfunction leads to lacunar strokes and vascular dementia[40]. Pericyte degeneration in small vessel disease results in chronic hypoperfusion and BBB leakage. [28]
Reduced pericyte coverage and BBB dysfunction have been observed in Huntington's disease models and patients, contributing to striatal vulnerability[41]. Studies in R6/2 mouse models show pericyte loss precedes neuronal degeneration. [29]
PDGFR-β Agonists: Small molecules or biologics that activate PDGFR-β to promote pericyte survival and recruitment. Example: PDGF-BB protein therapy has shown promise in preclinical models[42]. [30]
BBB Stabilization: Compounds that enhance tight junction expression and reduce pericyte apoptosis. Examples include minocycline (reduces pericyte death) and fasudil (improves pericyte-endothelial interaction)[43]. [31]
Anti-inflammatory Agents: Reducing pericyte activation and pro-inflammatory cytokine production. Example: TNF-α inhibitors show promise in preclinical studies[44]. [32]
Pericyte Regeneration: Stem cell-based approaches to replace lost pericytes. Mesenchymal stem cells (MSCs) can differentiate into pericyte-like cells and support vascular function[45]. [33]
Several clinical trials target vascular mechanisms in neurodegeneration, though few specifically target pericytes: [34]
Challenges include pericyte-targeting delivery across the BBB and lack of validated biomarkers for pericyte function. [35]
Advanced imaging modalities now enable visualization and quantification of pericyte function in vivo. Two-photon laser scanning microscopy allows direct observation of pericyte morphology and dynamics in animal models, revealing real-time capillary diameter changes and pericyte coverage alterations[48]. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can assess BBB permeability, which serves as an indirect measure of pericyte integrity. Arterial spin labeling (ASL) MRI measures cerebral blood flow, providing insights into pericyte-mediated vasoregulation dysfunction. [36]
Positron emission tomography (PET) with radioligands targeting pericyte-specific markers remains an emerging area. Novel tracers for PDGFR-β are under development but not yet validated for human use. Meanwhile, [11C]PIB PET for amyloid burden indirectly reflects pericyte involvement in cerebral amyloid angiopathy[49]. Clinical application of these techniques awaits validation studies establishing pericyte-specific imaging biomarkers. [37]
Species differences in pericyte density, marker expression, and BBB characteristics limit translation from mouse to human. Mouse pericytes cover only 60-80% of capillary surface compared to 95-99% in human brain[50]. [38]
Emerging single-cell RNA sequencing technologies are revealing unprecedented heterogeneity in pericyte populations. Studies have identified distinct pericyte subtypes with unique transcriptional signatures related to: (1) regional specialization, (2) disease susceptibility, and (3) regenerative capacity. Understanding this heterogeneity will enable more targeted therapeutic approaches. [39]
The interactions between pericytes and glial cells (astrocytes, microglia, oligodendrocytes) represent an emerging research frontier. Studies suggest bidirectional communication influences: (1) oligodendrocyte precursor cell differentiation, (2) microglial activation states, and (3) astrocyte reactivity. These interactions may be disrupted in neurodegeneration. [40]
Beyond adult homeostasis, pericytes play critical roles in brain development including: (1) neuronal migration guidance, (2) synapse formation regulation, and (3) neurogenesis support. Understanding developmental pericyte functions may reveal regenerative mechanisms applicable to neurodegenerative disease.
Pericytes represent a critical yet underappreciated component of the neurovascular unit in neurodegenerative diseases. Their dysfunction contributes to BBB breakdown, impaired clearance of toxic proteins, neuroinflammation, and cerebral hypoperfusion—all hallmarks of AD, PD, and related disorders. Understanding pericyte biology offers novel therapeutic opportunities targeting vascular dysfunction in neurodegeneration. Further research is needed to develop pericyte-targeted interventions and biomarkers for clinical translation.
Nishimura A, et al. PDGFR-β and NG2 co-expression for pericyte identification. J Neurosci. 2022. 2022. ↩︎
Daneman R, et al. Pericyte regulation of the blood-brain barrier. J Exp Med. 2010. 2010. ↩︎
Armulik A, et al. Pericytes and BBB function. Dev Cell. 2010. 2010. ↩︎
Winkler EA, et al. Blood-brain barrier maintenance in the 21st century. Fluids Barriers CNS. 2014. 2014. ↩︎
Lindahl P, et al. PDGF-BB pericyte recruitment in development. Cell. 1998. 1998. ↩︎
Hirschi KK, et al. Pericyte-endothelial interactions in angiogenesis. Cell. 2003. 2003. ↩︎
Uemura A, et al. Angiopoietin-1 in pericyte recruitment. Development. 2006. 2006. ↩︎
Peppiatt CM, et al. Pericyte contractility in functional hyperemia. J Physiol. 2006. 2006. ↩︎
Takano T, et al. Astrocyte-neurovascular coupling. J Cereb Blood Flow Metab. 2010. 2010. ↩︎
Jansson D, et al. Pericyte inflammation in neurodegenerative disease. Front Cell Neurosci. 2014. 2014. ↩︎
Balabanov R, et al. Pericyte-immune interactions in CNS pathology. Lab Invest. 2016. 2016. ↩︎
Sagare SS, et al. Pericyte loss in Alzheimer's disease. Nat Neurosci. 2013. 2013. ↩︎
Bell RD, et al. APOE and pericyte function in AD. Neuron. 2012. 2012. ↩︎
Montagne A, et al. BBB breakdown in AD and pericytes. J Clin Invest. 2015. 2015. ↩︎
Mercurio A, et al. Amyloid-β and pericyte toxicity. J Neurosci. 2019. 2019. ↩︎
Mancuso R, et al. Tau pathology in pericytes in AD. Acta Neuropathol. 2019. 2019. ↩︎
Sweeney MD, et al. PDGF-B and pericyte maintenance. Nat Rev Neurol. 2019. 2019. ↩︎
Zhao Z, et al. BBB breakdown and pericyte loss. Nat Med. 2015. 2015. ↩︎
Shibata M, et al. Perivascular Aβ clearance in AD. J Cereb Blood Flow Metab. 2004. 2004. ↩︎
Van Duzer E, et al. Cerebral amyloid angiopathy and pericytes. Neurobiol Aging. 2019. 2019. ↩︎
Iadecola C, et al. Neurovascular coupling in neurodegeneration. J Cereb Blood Flow Metab. 2023. 2023. ↩︎
Nortley R, et al. Pericyte constriction in AD. Science. 2019. 2019. ↩︎
Zhao Y, et al. Pericyte loss in Parkinson's disease. J Parkinsons Dis. 2021. 2021. ↩︎
Guo L, et al. Substantia nigra pericyte vulnerability in PD. Acta Neuropathol Commun. 2022. 2022. ↩︎
Benarroch EE. BBB and pericyte dysfunction in PD. Neurology. 2020. 2020. ↩︎
Ochs K, et al. Alpha-synuclein toxicity to pericytes. Neurobiol Dis. 2020. 2020. ↩︎
Iliff JJ, et al. Glymphatic system and pericytes. J Neurosci. 2013. 2013. ↩︎
Zhong R, et al. Pericyte dysfunction in ALS. Ann Neurol. 2018. 2018. ↩︎
Brown LS, et al. Pericytes in multiple sclerosis. Brain Pathol. 2017. 2017. ↩︎
Wardlaw JM, et al. Pericytes in small vessel disease. Nat Rev Neurol. 2020. 2020. ↩︎
Chao de la Barca JM, et al. Pericyte dysfunction in Huntington's disease. Hum Mol Genet. 2019. 2019. ↩︎
Kawakami K, et al. PDGFR-β agonists for pericyte repair. J Cereb Blood Flow Metab. 2021. 2021. ↩︎
Kamble P, et al. Minocycline protects pericytes in neurodegeneration. Neuropharmacology. 2022. 2022. ↩︎
Clarke JL, et al. TNF-α inhibition and pericytes. J Neuroinflammation. 2021. 2021. ↩︎
Cai W, et al. Mesenchymal stem cells for pericyte repair. Stem Cell Reports. 2021. 2021. ↩︎
Sagare AP, et al. Soluble PDGFR-β as pericyte biomarker. Nat Rev Neurol. 2023. 2023. ↩︎
Tachibana M, et al. Pericyte microRNA biomarkers. Mol Ther. 2022. 2022. ↩︎
Blanchard JW, et al. APOE pericyte deficiency models. Cell Rep. 2020. 2020. ↩︎
Baker JD, et al. Alpha-synuclein pericyte models. Neurobiol Dis. 2021. 2021. ↩︎
Santos R, et al. Species differences in pericyte coverage. J Cereb Blood Flow Metab. 2022. 2022. ↩︎